KiOmed Pharma

Executive Summary

KiOmed Pharma is a Belgian biotech company leveraging its proprietary animal-free carboxymethyl chitosan (CM-chitosan) platform to develop and commercialize medical devices for ophthalmology and osteoarthritis. Founded in 2017, the company targets high-impact pathologies including dry eye disease, skin aging, and osteoarthritis by harnessing the biopolymer's unique lubricating, protective, and hydrating properties. KiOmed's lead product, KiOmedine® for dry eye, has received CE marking and is marketed in Europe, with ongoing efforts to expand into additional indications such as osteoarthritis and skincare. The technology differentiates itself through its non-animal origin, biocompatibility, and multifunctional mode of action, positioning the company for growth in the medical aesthetics and regenerative medicine markets.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for KiOmedine® in the U.S. dry eye market60% success
• Q4 2026Positive Phase 2b results for KiOmedine® in knee osteoarthritis gel formulation50% success
• H2 2026Exclusive distribution partnership for Asia-Pacific region70% success